EcoDrugPlus

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSLLEG00000029760
Gene Symbol: GRIN2C
1 View Cross-references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 2d

Ensembl ID : ENSLLEG00000014407
Gene Symbol: GRIN2D
1 View Cross-references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSLLEG00000000881
Gene Symbol: GRIN3A
1 View Cross-references
245 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSLLEG00000027861
Gene Symbol: GRIN3B
1 View Cross-references
286 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSLLEG00000006327
Gene Symbol: GRIK1
1 View Cross-references
302 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSLLEG00000018681
Gene Symbol: GRIK2
1 View Cross-references
334 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSLLEG00000002394
Gene Symbol: GRIK3
1 View Cross-references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSLLEG00000013044
Gene Symbol: GRIK5
1 View Cross-references
303 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSLLEG00000019050
Gene Symbol: GRM2
1 View Cross-references
276 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSLLEG00000015613
Gene Symbol: GRM3
1 View Cross-references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSLLEG00000023527
Gene Symbol: GRM5
1 View Cross-references
284 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutaminase

Ensembl ID : ENSLLEG00000023187
Gene Symbol: GLS
1 View Cross-references
307 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).